SCNX · Scienture Holdings, Inc.
$0.39
0.00 (-1.24%)
At close · Aug 31
Going-concern doubt
— cleared Aug 13, 2026
The latest filing states the doubt was alleviated.
“While these factors initially indicated substantial doubt about the ability of the Company to continue as a going concern, management believes that its existing cash on hand, revenues from the commercialization of ARBLI™ (SCN-102) and REZENOPY™ (SCN-110) and its planned financing activities alleviate that doubt.”View the 10-Q filed Aug 13, 2026
Market Cap
$16.18M
Shares
41.06M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$431.61K
+215.9%
FY2025
Net Income
-$41.51M
-557.9%
FY2025
Gross Margin
76.8%
+72.4pp
FY2025
Operating Margin
-9867.92%
+890.8pp
FY2025
Diluted EPS
-$2.70
-208.9%
FY2025
Operating Cash Flow
-$13.38M
+6.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $821.32K | $431.61K | $136.64K | $1.36M | $10.25M | $9.89M | $17.12M | $7.44M | $3.83M | $2.93M | $2.48M | $2.91M | $1.5M | $955.88K | |
| $100.88K | $100.13K | $130.64K | $1.31M | $4.73M | $5.14M | $11.42M | $2.57M | $449.05K | — | $16.36K | $189.84K | $440.05K | $944.07K | |
| $720.44K | $331.48K | $6005 | $49.03K | $5.52M | $4.75M | $5.71M | $4.87M | $3.38M | $2.93M | $2.48M | $2.72M | $1.06M | $11.81K | |
| — | 76.8% | 4.39% | 3.6% | 53.85% | 47.99% | 33.33% | 65.5% | 88.28% | 100% | 100% | 93.48% | 70.59% | 1.24% | |
| $2.5M | $1.96M | $2.24M | — | — | — | — | — | — | — | — | — | — | — | |
| $5.09M | $7.93M | $6.68M | $1.34M | $1.69M | $1.9M | $7.49M | $4.38M | $3.47M | $2.54M | $3.49M | $2.86M | $2.49M | $2.1M | |
| — | $907.69K | — | $814.79K | $44.1K | — | — | — | — | — | — | — | — | — | |
| — | $491.78K | — | — | — | — | — | — | — | — | — | — | — | — | |
| $40.79M | $42.92M | $14.71M | $4.45M | $8.44M | $10.04M | $8.21M | $4.75M | $3.47M | — | — | — | — | — | |
| -$40.07M | -$42.59M | -$14.7M | -$4.4M | -$2.92M | -$5.29M | -$2.51M | $125.22K | -$87.62K | $395.1K | -$1.01M | -$137.07K | -$1.43M | -$2.08M | |
| — | -9867.92% | -10758.7% | -322.36% | -28.45% | -53.51% | -14.64% | 1.68% | -2.29% | 13.48% | -40.59% | -4.71% | -95.67% | -218.02% | |
| — | -$42.1M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $3.07M | $4.08M | $1.34M | $1.2M | $336.21K | $23.59K | $29.39K | $53.23K | $57.54K | $157.06K | $151.5K | $119.51K | $4154 | $7281 | |
| $123.64K | -$916.3K | -$4.08M | -$4.09M | $512.53K | -$23.59K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$250K | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -$250K | — | — | — | — | — | — | |
| — | -$43.51M | -$18.78M | -$8.48M | — | — | — | — | — | — | — | — | — | — | |
| — | -$1.99M | -$534.4K | — | — | — | — | — | — | — | — | — | — | — | |
| -$37.95M | -$41.51M | $9.07M | -$17.84M | -$3.47M | -$5.32M | -$2.54M | -$284.43K | $9038 | $288.98K | -$2.76M | -$1.12M | -$2.01M | -$2.09M | |
| — | -9618.03% | 6634.66% | -1308.34% | -33.87% | -53.75% | -14.81% | -3.82% | 0.24% | 9.86% | -111.21% | -38.36% | -134.47% | -218.78% | |
| — | — | — | — | -$437.77K | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$3.47M | -$5.32M | -$2.54M | — | — | — | — | — | — | — | |
| USD/shares | -$2.04 | -$2.70 | $2.69 | -$23.35 | -$6.15 | -$9.75 | — | -$0.75 | $0.00 | $0.15 | -$1.35 | -$0.60 | -$1.05 | -$2.25 |
| USD/shares | -$2.04 | -$2.70 | $2.48 | -$23.35 | -$6.13 | -$9.75 | — | -$0.75 | $0.00 | $0.15 | -$1.35 | -$0.60 | -$1.05 | -$2.25 |
| shares | — | 15.35M | 3.38M | 764.06K | 564.86K | 542.45K | 513.71K | 395.27K | 358.45K | 2.13M | 2.1M | 2.09M | 1.99M | 940.11K |
| shares | — | 15.35M | 3.65M | 2.38M | 566.61K | 542.45K | 513.71K | 395.27K | 388.43K | 2.27M | 2.1M | 2.09M | 1.99M | 940.11K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $17.05M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Integra | $136,643 | $1,363,830 | — | — | — |
| Community Specialty Pharmacy LLC | — | — | — | $1,652,841 | $1,653,924 |
| Integra | — | — | $4,754,067 | — | — |
| Integra Pharma LLC | — | — | — | $3,250,561 | $9,877,067 |
| Trxade Inc | — | — | $5,435,814 | $4,924,015 | $5,546,746 |
| All Other Segments | — | — | $60,287 | $62,016 | $44,783 |
By Geography (USD)
| Component | FY2024 |
|---|---|
| United States | $136,643 |
By Product & Service (USD)
| Component | FY2023 | FY2022 |
|---|---|---|
| Service Revenue | $6,421,363 | $5,496,101 |
| Product Revenue | $1,850,851 | $4,754,067 |
Key facts
CIK
1382574
CUSIP
80880X104
13F (30d)
13 filings
13 filers
Visit website
Investor relations